Abstract: Methods and kits for identifying an increased risk of developing preeclampsia in a pregnant woman based on expression pattern of non-coding RNAs in body fluids are provided. In particular, the methods provide information for identifying a pregnant woman as being at risk of developing preeclampsia by analyzing the pattern of non-coding RNAs in body fluids during early stages of pregnancy.

Abstract: A method of fetal genotyping, comprises receiving maternal genomic DNA (gDNA) data, maternal cell-free DNA (cfDNA) data, and paternal gDNA data of a pair parenting to a fetus. The data are analyzed to identify a first set of sites at which the parents are homozygous for different alleles, and a second set at which at least one of the parents has a mutation. For each site of the first set, a probability that a respective portion of the maternal cfDNA data is derived from the fetus is determined. Each site of the second set is classified according to the determined probabilities as being either fetal or maternal to genotype the fetus.

Abstract: Methods and kits for identifying an increased risk of developing preeclampsia in a pregnant woman based on expression pattern of non-coding RNAs in body fluids are provided. In particular, the methods provide information for identifying a pregnant woman as being at risk of developing preeclampsia by analyzing the pattern of non-coding RNAs in body fluids during early stages of pregnancy.

Abstract: Provided are compositions and methods for treating cancer, particularly solid tumors, and cancer metastasis, using micro-RNAs mi R-96 and/or mi R-182.

Abstract: Provided herein are compositions that include a metal nanoparticle functionalized with a miRNA and a targeting molecule. The compositions may be used to prevent or reduce the rate of metastasis of cancer cells. The compositions also may include a drug, such as a chemotherapeutic agent. The compositions also may include a hydrogel in which the metal nanoparticles are dispersed. Methods of miRNA and/or drug delivery and kits also are provided.

Abstract: Provided are compositions and methods for treating cancer, particularly solid tumors, and cancer metastasis, using micro-RNAs mi R-96 and/or mi R-182.

Abstract: There is provided a method for matching subject data to database patient data based on matching phenotypes and related genetic sequences, comprising: receiving a dataset including at least one phenotype disease description of a subject and a genetic sequence of the subject, the phenotype disease description describing clinically significant manifestations of disease in the subject; calculating a ranking score for each of a dataset of patients, the ranking score indicative of a similarity correlation between the dataset of each respective patient and the dataset of the subject, wherein the related genetic sequences of the dataset of patients are underlying genetic mutations attributable to the at least one phenotypic disease description; matching the dataset of the subject with at least one dataset of patients according to a requirement of the ranking score; and providing data indicative of the matched patients.

Abstract: The present invention relates to methods for diagnosing, staging, prognosticating and treating melanoma based on evaluating the expression of specific patterns of oncogenic or suppressive microRNA (miR) molecules in a patient in need thereof.

Abstract: The present invention relates to methods for diagnosing, staging, prognosticating and treating melanoma based on evaluating the expression of specific patterns of oncogenic or suppressive microRNA (miR) molecules in a patient in need thereof.

Abstract: There is provided a method for the detection and identification of infection of a subject by a microorganism, wherein the method is based on the use of small RNA derived sequences and subtraction and assembly thereof.

Abstract: The present invention relates to methods for diagnosing, staging, prognosticating and treating melanoma based on evaluating the expression of specific patterns of oncogenic or suppressive microRNA (miR) molecules in a patient in need thereof.

Abstract: The present invention relates to polymorphic binding sites for micro-RNA and to micro-RNA-based cancer diagnosis, cancer therapy and personalized medicine. In particular, the present invention relates to diagnosis, therapy and personalized medicine with the specific miR-515-5p molecule.

Abstract: The present invention relates to polynucleotides comprising Alu-derived exons derived by alternative splicing from Alu elements, which are involved in cancer and genetic diseases. The present invention further relates to use of oligonucleotides for identification of the sequences associated with Alu exonization for diagnosis and treatment of cancer and genetic diseases.